LAUSR

characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323: 1061–1069. 4. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol 2020;11:827. 5. Lee J, Park SS, Kim TY, Lee DG, Kim DW. Lymphopenia as a biological predictor of outcomes in COVID-19 patients: a nationwide cohort study. Cancers (Basel) 2021;13:471. 6. Niu J, Sareli C, Mayer D, Visbal A, Sareli A. Lymphopenia as a predictor for adverse clinical outcomes in hospitalized patients with COVID-19: a single center retrospective study of 4485 cases. J Clin Med 2022;11:700. 7. Adamo S, Chevrier S, Cervia C, Zurbuchen Y, Raeber ME, Yang L, et al. Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19. Allergy 2021;76:2866–2881. 8. Popescu I, Snyder ME, Iasella CJ, Hannan SJ, Koshy R, Burke R, et al. CD4 T-cell dysfunction in severe COVID-19 disease is tumor necrosis factor-a/tumor necrosis factor receptor 1–dependent. Am J Respir Crit Care Med 2022;205:1403–1418. 9. Mehta AK, Gracias DT, Croft M. TNF activity and T cells. Cytokine 2018; 101:14–18. 10. Mak TW, Yeh WC. Signaling for survival and apoptosis in the immune system. Arthritis Res 2002;4:S243–S252. 11. Winkler ES, Bailey AL, Kafai NM, Nair S, McCune BT, Yu J, et al. SARS-CoV-2 infection in the lungs of human ACE2 transgenic mice causes severe inflammation, immune cell infiltration, and compromised respiratory function [preprint]. bioRxiv; 2020 [accessed 2022 Mar 24]. Available from: https://www.biorxiv.org/ content/10.1101/2020.07.09.196188v1. 12. Gawish R, Starkl P, Pimenov L, Hladik A, Lakovits K, Oberndorfer F, et al. ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNFand IFNg-driven immunopathology. eLife 2022;11:e74623. 13. Robinson PC, Richards D, Tanner HL, Feldmann M. Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. Lancet Rheumatol 2020;2: e653–e655. 14. Kokkotis G, Kitsou K, Xynogalas I, Spoulou V, Magiorkinis G, Trontzas I, et al. Systematic review with meta-analysis: COVID-19 outcomes in patients receiving anti-TNF treatments. Aliment Pharmacol Ther 2022; 55:154–167.